Qingdao Huanghai Pharmaceutical

Qingdao Huanghai Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the development and manufacturing of oral solid dosage forms, with a particular focus on sustained-release and controlled-release technologies. Founded in 1959, the company has established itself as a market leader in the cardiovascular segment in China, primarily driven by its flagship nifedipine sustained-release products. Beyond cardiovascular health, its portfolio includes treatments for endocrine disorders, neurological conditions, and pain management. Huanghai Pharmaceutical operates advanced GMP-certified production lines and maintains a strong presence in both domestic and international markets through its integrated R&D and manufacturing capabilities. The company is recognized for its technical expertise in complex drug delivery systems and continues to expand its reach through a robust distribution network.